CUR - Neuralstem, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.3000
+0.0500 (+4.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.2500
Open1.2900
Bid0.0000 x 900
Ask0.0000 x 1300
Day's Range1.2200 - 1.3000
52 Week Range1.1000 - 24.2000
Volume31,638
Avg. Volume117,712
Market Cap3.351M
Beta (3Y Monthly)2.78
PE Ratio (TTM)N/A
EPS (TTM)-7.8300
Earnings DateAug 9, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
Trade prices are not sourced from all markets
  • PR Newswire

    Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)

    GERMANTOWN, Md., Oct. 3, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced the adjustment of an options award that was previously approved in accordance with Nasdaq Listing Rule 5635(c)(4). On December 18, 2018, Neuralstem announced the grant of a non-qualified inducement stock option pursuant to Nasdaq Listing Rule 5635(c)(4) to Dr. Kenneth Carter as an inducement for his employment by the company. On July 31, 2019, Neuralstem closed an underwritten offering of its securities resulting in the issuance of 2,777,777 units.  As a result of the offering, the number of shares into which Dr. Carter's inducement grant is exercisable into was increased from 40,000 to 156,213.

  • PR Newswire

    Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

    GERMANTOWN, Md., Sept. 24, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced completion of subject enrollment in its Phase 2 clinical trial of NSI-566 for the treatment of chronic ischemic stroke.  NSI-566 is Neuralstem's lead stem cell therapy candidate, and has also been evaluated in clinical trials for patients with Amyotrophic Lateral Sclerosis and chronic spinal cord injury. The trial is being conducted at the BaYi Brain Hospital (affiliated to the 7th Medical Center of the PLA General Hospital) in Beijing, China under the direction of Professor Xu Ruxiang.

  • PR Newswire

    Neuralstem Reports Second Quarter 2019 Fiscal Results

    GERMANTOWN, Md. , Aug. 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small ...

  • PR Newswire

    Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing

    GERMANTOWN, Md., Aug. 7, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR) ("Neuralstem" or the  Company") today announced that on August 6, 2019, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for continued listing of the Company's stock on the Nasdaq Stock Market.

  • PR Newswire

    Neuralstem Closes $7.5 Million Underwritten Public Offering

    GERMANTOWN, Md., July 31, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR) ("Neuralstem" or the "Company") today announced the closing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit resulting in  gross proceeds of approximately $7,500,000, before deducting discount,  commissions and estimated offering expenses. Each unit issued was comprised of one share of common stock (or common stock equivalent), one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock (collectively, a "warrant combination").

  • PR Newswire

    Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering

    GERMANTOWN, Md., July 25, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR) ("Neuralstem" or the "Company") today announced the pricing of its underwritten public offering of an aggregate of 2,777,777 units at a public offering price of $2.70 per unit for gross proceeds of approximately $7,500,000, before deducting discount and commissions and estimated offering expenses. Each unit is comprised of one share of common stock (or common stock equivalent), one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock (collectively, a "warrant combination").

  • PR Newswire

    Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors

    GERMANTOWN, Md., July 18, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced that Mary Ann Gray, Ph.D. has been appointed to the Company's Board of Directors. "We are pleased to welcome Mary Ann to our board, her expertise and leadership pharmaceutical and biotech industry will be a great asset to Neuralstem," said Dr. Ken Carter, Executive Chairman of the Board. "Both Dr. Gray's substantial background in pharmacology and finance—as well as—her dedication to developing new treatments, reflects our shared commitment here at Neuralstem to improve patient outcomes.

  • PR Newswire

    Neuralstem Announces a 1-for-20 Reverse Stock Split

    GERMANTOWN, Md., July 16, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective on Wednesday, July 17, 2019 after market close and shares of Neuralstem Inc. common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "CUR," at the market open on Thursday, July 18, 2019.

  • PR Newswire

    Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients

    GERMANTOWN, Md., July 1, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open label Phase 1 clinical trial evaluating the feasibility and safety of transplantation of its lead stem cell asset, NSI-566, for the treatment of motor deficits due to ischemic stroke. The manuscript, entitled 'Stable Intracerebral Transplantation of Neural Stem Cells for the Treatment of Paralysis Due to Ischemic Stroke,' summarizes the results of an open label trial performed at BaYi Brain Hospital in Beijing, China, with Principal Investigator Professor Xu Ruxiang.

  • PR Newswire

    Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells

    GERMANTOWN, Md. , May 16, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced the expansion of their ...

  • PR Newswire

    Neuralstem Reports First Quarter 2019 Fiscal Results

    - Kenneth C. Carter, PhD appointed Executive Chairman - Strategic initiative to expand pipeline announced GERMANTOWN, Md. , May 14, 2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical ...

  • PR Newswire

    Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors

    GERMANTOWN, Md., May 6, 2019 /PRNewswire/ -- Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, announced that David J. Mazzo, Ph.D. has been appointed to the Company's Board of Directors to be effective June 12, 2019. Dr. Mazzo will replace Stanley Westreich, who is retiring on the effective date. "Dr. Mazzo is a seasoned executive in the biopharma space and brings Neuralstem significant value gained over his 30 years in the pharmaceutical and biotech industries," said Dr. Ken Carter, Executive Chairman of the Board.

  • Some Neuralstem (NASDAQ:CUR) Shareholders Have Copped A 99% Share Price Wipe Out
    Simply Wall St.

    Some Neuralstem (NASDAQ:CUR) Shareholders Have Copped A 99% Share Price Wipe Out

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While not a mind-blowing move, it is good to see that the Neuralstem, Inc. (NASDAQ:CUR) share pric...

  • GlobeNewswire

    Neuralstem Reports Year End 2018 Fiscal Results

    GERMANTOWN, Md., March 22, 2019 -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem.

  • PR Newswire

    Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort

    Neuralstem Engages Strategic Advisors to Evaluate Dozens of New Technologies GERMANTOWN, Md. , Feb. 7, 2019 /PRNewswire/ --  Neuralstem, Inc. (NASDAQ: CUR), a biopharmaceutical company focused on the development ...

  • GlobeNewswire

    Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board

    Neuralstem, Inc. (CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, appointed Kenneth C. Carter, Ph.D., as the Company’s Executive Chairman of the Board to be effective on January 1, 2019. Dr. Carter will replace interim CEO, Jim Scully, who will be stepping down. “Dr. Carter brings a wealth of drug development expertise and executive leadership having led both private and public biotechnology companies.

  • How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)?
    Simply Wall St.

    How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)?

    Neuralstem Inc (NASDAQ:CUR), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CUR will Read More...

  • GlobeNewswire

    Market Trends Toward New Normal in Neuralstem, Industrial Services of America, Gulf Resources, Natural Alternatives International, Lifevantage, and Lonestar Resources US — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update

    - NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome - - Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke - -.